Radiation plus chemo for borderline resectable pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether giving radiation therapy before a combination of two chemotherapy drugs (NALIRIFOX) is better than chemotherapy alone for people with pancreatic cancer that is on the edge of being removable. The goal is to see if adding radiation helps shrink the tumor enough to make surgery possible and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have pancreatic cancer that doctors consider borderline resectable (can potentially be removed with surgery).
- You cannot have had any prior treatment (chemo, radiation, etc.) for your pancreatic cancer.
- You need to be in generally good health (able to do daily activities and care for yourself).
- You must have adequate organ function (your liver, kidneys, and bone marrow need to be working well enough).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines focused radiation with a chemotherapy drug combo to help shrink or control locally advanced pancreatic cancer. If it works, this treatment might make the tumor smaller and improve quality of life.
This trial tests whether giving proton radiation and chemotherapy before surgery can shrink or control “borderline resectable” pancreatic cancer so it can be removed more effectively. It may help by improving treatment response while planning for surgery afterward.
This trial tests a combination of four drugs (liposomal irinotecan, 5-fluorouracil, oxaliplatin, and adebrelimab) given with radiation therapy before surgery for pancreatic cancer that can be surgically removed or is borderline removable. The goal is to shrink the tumor and improve the chances of successful surgery.
This trial tests a combination of two chemotherapy regimens (AG and FOLFIRINOX) with an immunotherapy drug (a PD-L1 antibody) before surgery for pancreatic cancer that is borderline resectable or locally advanced. The goal is to shrink the tumor enough to allow successful surgery.
This trial tests a combination of standard chemotherapy, MRI-guided radiation, and surgery for people with locally advanced pancreatic cancer that might be removable. The goal is to see if this approach can make more tumors resectable.
This trial tests a combination of chemotherapy drugs given before and after surgery for pancreatic cancer that is considered high-risk but removable. The goal is to see if this approach can improve outcomes for patients with this type of cancer.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.